SCHEMBL4763607

SCHEMBL4763607

CCN1CCN(c2nc(C(OC(=O)C(=O)OC(c3cc4ccccc4c(N4CCN(CC)CC4)n3)c3ccccc3OC)c3ccccc3OC)cc3ccccc23)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
USP2 O75604 2/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
KDM4E B2RXH2 3/20 0.39
MAPT P10636 3/20 0.39
HPGD P15428 2/20 0.39
APOBEC3A P31941 1/20 0.39
RAD52 P43351 1/20 0.39
RAB9A P51151 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773636 0.86 ALDH1A1 (0.44) ALDH1A1LMNAPOLBKMT2AMEN1
SCHEMBL4769437 0.85 MEN1 (0.44) ALDH1A1USP2LMNATP53POLB
Oxalic Acid SCHEMBL4763602 0.85 ALDH1A1 (0.44) ALDH1A1USP2LMNATP53POLB
SCHEMBL4771992 0.76 CHRM5 (0.48) ALDH1A1USP2LMNATP53POLB
Oxalic Acid SCHEMBL6292021 0.74 ALDH1A1 (0.46) ALDH1A1LMNAKMT2AMEN1KDM4E
Oxalic Acid SCHEMBL4773633 0.74 ALDH1A1 (0.46) ALDH1A1USP2LMNATP53POLB
SCHEMBL4772543 0.74 MEN1 (0.46) ALDH1A1LMNAKMT2AMEN1KDM4E
SCHEMBL4768653 0.74 CYP1A2 (0.48) ALDH1A1USP2LMNAKMT2AMEN1
Oxalic Acid SCHEMBL4765656 0.74 ALDH1A1 (0.48) ALDH1A1USP2LMNATP53POLB
Oxalic Acid SCHEMBL4765120 0.74 CHRM5 (0.46) ALDH1A1USP2LMNATP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 ALDH1A1 2989/4885USP2 3459/4885LMNA 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.